These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37110126)

  • 21. Can we selectively target AML stem cells?
    Jordan CT
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101100. PubMed ID: 31779978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leukemic stem cells and therapy resistance in acute myeloid leukemia.
    Stelmach P; Trumpp A
    Haematologica; 2023 Feb; 108(2):353-366. PubMed ID: 36722405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.
    Venugopal S; Takahashi K; Daver N; Maiti A; Borthakur G; Loghavi S; Short NJ; Ohanian M; Masarova L; Issa G; Wang X; Carlos BR; Yilmaz M; Kadia T; Andreeff M; Ravandi F; Konopleva M; Kantarjian HM; DiNardo CD
    Blood Cancer J; 2022 Jan; 12(1):10. PubMed ID: 35078972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells.
    Jones CL; Stevens BM; D'Alessandro A; Reisz JA; Culp-Hill R; Nemkov T; Pei S; Khan N; Adane B; Ye H; Krug A; Reinhold D; Smith C; DeGregori J; Pollyea DA; Jordan CT
    Cancer Cell; 2018 Nov; 34(5):724-740.e4. PubMed ID: 30423294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost-Utility Analysis.
    Guinan K; Mathurin K; Au Y; Schuh AC; Bui CN; Chai X; Lachaine J
    Curr Oncol; 2022 Oct; 29(10):7524-7536. PubMed ID: 36290869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid and Efficient Response to Gilteritinib and Venetoclax-Based Therapy in Two AML Patients with FLT3-ITD Mutation Unresponsive to Venetoclax Plus Azacitidine.
    Zhang LS; Wang J; Xu MZ; Wu TM; Huang SM; Cao HY; Sun AN; Liu SB; Xue SL
    Onco Targets Ther; 2022; 15():159-164. PubMed ID: 35221695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful combination treatment with azacitidine and venetoclax as a bridging therapy for third allogenic stem cell transplantation in a patient with 11q23/MLL-rearranged complex karyotype acute myeloid leukemia.
    Edahiro T; Ureshino H; Chishaki R; Fujino K; Mino T; Yoshida T; Fukushima N; Ichinohe T
    EJHaem; 2023 Feb; 4(1):273-275. PubMed ID: 36819153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations.
    Desikan SP; Ravandi F; Pemmaraju N; Konopleva M; Loghavi S; Jabbour EJ; Daver N; Jain N; Chien KS; Maiti A; Montalban-Bravo G; Kadia TM; Macaron W; DeLumpa R; Kwari M; Borthakur G; Short NJ
    Acta Haematol; 2022; 145(5):529-536. PubMed ID: 35717939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.
    Fleischmann M; Scholl S; Frietsch JJ; Hilgendorf I; Schrenk K; Hammersen J; Prims F; Thiede C; Hochhaus A; Schnetzke U
    J Cancer Res Clin Oncol; 2022 Nov; 148(11):3191-3202. PubMed ID: 35099591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A retrospective comparison of salvage intensive chemotherapy
    Park S; Kwag D; Kim TY; Lee JH; Lee JY; Min GJ; Park SS; Yahng SA; Jeon YW; Shin SH; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Lee JW; Kim HJ
    Ther Adv Hematol; 2022; 13():20406207221081637. PubMed ID: 35340720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simultaneous inhibition of Sirtuin 3 and cholesterol homeostasis targets acute myeloid leukemia stem cells by perturbing fatty acid β-oxidation and inducing lipotoxicity.
    O'Brien C; Ling T; Berman JM; Culp-Hill R; Reisz JA; Rondeau V; Jahangiri S; St-Germain J; Macwan V; Astori A; Zeng A; Hong JY; Li M; Yang M; Jana S; Gamboni F; Tsao E; Liu W; Dick JE; Lin H; Melnick A; Tikhonova A; Arruda A; Minden MD; Raught B; D'Alessandro A; Jones CL
    Haematologica; 2023 Sep; 108(9):2343-2357. PubMed ID: 37021547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of Invasive Fungal Infections in Patients With Previously Untreated Acute Myeloid Leukemia Receiving Venetoclax and Azacitidine.
    Zhang A; Johnson T; Abbott D; Phupitakphol T; Gutman JA; Pollyea DA; Koullias Y
    Open Forum Infect Dis; 2022 Oct; 9(10):ofac486. PubMed ID: 36225746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with
    Daido Y; Sugiura H; Ishikawa T; Kuroi T; Okamoto S; Nomura N; Masunari T; Sezaki N; Nannya Y; Ogawa S; Tanimoto M
    Case Rep Oncol; 2023; 16(1):999-1006. PubMed ID: 37900854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oxidative Phosphorylation Fueled by Fatty Acid Oxidation Sensitizes Leukemic Stem Cells to Cold.
    Griessinger E; Pereira-Martins D; Nebout M; Bosc C; Saland E; Boet E; Sahal A; Chiche J; Debayle D; Fleuriot L; Pruis M; De Mas V; Vergez F; Récher C; Huls G; Sarry JE; Schuringa JJ; Peyron JF
    Cancer Res; 2023 Aug; 83(15):2461-2470. PubMed ID: 37272750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential Combination of FLAM and Venetoclax plus Azacitidine to Bridge to Cord Blood Transplantation in a Patient with Primary Induction Failure Acute Myeloid Leukemia.
    Murakami H; Matsuoka KI; Asano T; Moriyama T; Matsumura A; Fujiwara H; Asada N; Ennishi D; Nishimori H; Fujii K; Fujii N; Toji T; Yoshino T; Maeda Y
    Case Rep Oncol; 2022; 15(3):974-979. PubMed ID: 36636684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipids and the cancer stemness regulatory system in acute myeloid leukemia.
    Lim INX; Nagree MS; Xie SZ
    Essays Biochem; 2022 Sep; 66(4):333-344. PubMed ID: 35996953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis.
    Jin S; Cojocari D; Purkal JJ; Popovic R; Talaty NN; Xiao Y; Solomon LR; Boghaert ER; Leverson JD; Phillips DC
    Clin Cancer Res; 2020 Jul; 26(13):3371-3383. PubMed ID: 32054729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
    DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
    Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis.
    Hurrish KH; Su Y; Patel S; Ramage CL; Carter JL; Edwards H; Buck SA; Wiley SE; Hüttemann M; Polin L; Kushner J; Dzinic SH; White K; Bao X; Li J; Yang J; Boerner J; Hou Z; Al-Atrash G; Konoplev SN; Busquets J; Tiziani S; Matherly LH; Taub JW; Konopleva M; Ge Y; Baran N
    Res Sq; 2023 Apr; ():. PubMed ID: 37162954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases.
    Wang N; He J; Liu F
    Chemotherapy; 2022; 67(3):178-182. PubMed ID: 35306492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.